Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Milestone Pharmaceuticals ( (MIST) ) just unveiled an update.
Milestone Pharmaceuticals announced its third-quarter financial results and provided updates on its regulatory and corporate activities. The company is preparing for the potential FDA approval of its CARDAMYST nasal spray for PSVT, with a target date set for December 13, 2025. Milestone has bolstered its financial resources through a successful equity offering and an amended royalty purchase agreement, positioning itself for a successful product launch. The company is also advancing its clinical program for etripamil in AFib-RVR, with plans to enter a pivotal Phase 3 trial. These developments highlight Milestone’s strategic focus on expanding its market presence and addressing unmet medical needs in cardiovascular treatment.
The most recent analyst rating on (MIST) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Underperform.
Milestone Pharmaceuticals’ overall stock score reflects substantial financial difficulties, including no revenue and negative cash flows. However, the upcoming launch of CARDAMYST provides a potential turnaround opportunity, which is a significant positive factor. Technical indicators suggest a bearish trend, and valuation metrics highlight the lack of earnings and dividends, indicating a speculative investment.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals is a company in the pharmaceutical industry focused on developing treatments for cardiovascular conditions. Their primary product is CARDAMYST, an etripamil nasal spray aimed at treating paroxysmal supraventricular tachycardia (PSVT) and potentially atrial fibrillation with rapid ventricular rate (AFib-RVR).
Average Trading Volume: 1,290,554
Technical Sentiment Signal: Buy
Current Market Cap: $157.2M
See more insights into MIST stock on TipRanks’ Stock Analysis page.
